Molnupiravir is an antiviral medication developed for the treatment of COVID-19. It works by interfering with the replication process of the virus, ultimately inhibiting its ability to spread within the body. It's taken orally and has shown promise in reducing the severity of illness and the duration of symptoms in clinical trials. It's particularly notable because it can be taken at home, potentially reducing the burden on healthcare systems. However, like any medication, it's important to consult with healthcare professionals before using it, as they can provide guidance on its appropriateness and potential side effects.
| Product Name | Molnupiravir (EIDD-2801) |
|---|---|
| COA | Available |
| CAS | 2349386-89-4 |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 Years |
| Molecular Formula | C13H19N3O7 |
| Manufacturer | LongilatBio |
| Purity | 99% |
| Country of Origin | China |
| Generic Name | EIDD-2801 |
| Key Features | Antiviral, Molnupiravir, EIDD-2801, 2349386-89-4, C13H19N3O7, LongilatBio, 99%, 200 Mg, China, 2 Year |
Molnupiravir is a highly effective antiviral medication initially developed to combat influenza. Through its mechanism of action, it hinders the replication of RNA viruses, making it a potential treatment for various viral diseases.
The medication works by introducing errors into the genetic material of the virus during the replication process. This ultimately results in the production of either non-functional or less infectious viral particles, effectively disrupting the spread of the virus within the body. As a result, molnupiravir can alleviate the severity of infection and aid in the recovery process.
One viral disease that could potentially benefit from molnupiravir is Feline Infectious Peritonitis (FIP). FIP is caused by certain strains of feline coronavirus and can be challenging to treat with limited treatment options available. Sadly, it often leads to fatality in affected cats.
Given that FIP is a coronavirus, an RNA virus, molnupiravir's mechanism of action targeting RNA viruses may prove useful. By introducing errors into the genetic material of the feline coronavirus, it may decrease the production of infectious particles and lessen the severity of symptoms in infected cats. This potential treatment brings hope for managing FIP and improving outcomes for affected felines.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
